7.36

2.77% -0.21

After Hours: 7.36

Larimar Therapeutics Inc (LRMR)

Overview News Price History Option Chain Financials Discussions Forecast

Larimar Therapeutics Inc stock is traded at $7.36, with a volume of 736.02K. It is down -2.77% in the last 24 hours and up +10.68% over the past month. Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Previous Close:

$7.57

Open:

$7.49

24h Volume:

736.02K

Relative Volume:

1.30

Market Cap:

$477.27M

Revenue:

Net Income/Loss:

$-36.95M

P/E Ratio:

-8.00

EPS:

-0.92

Net Cash Flow:

$-33.46M

1W Performance:

-5.40%

1M Performance:

+10.68%

6M Performance:

-5.22%

1Y Performance:

+130.36%

1-Day Range:

$7.20

$7.59

1-Week Range:

$7.20

$8.77

52-Week Range:

$2.18

$13.68

Larimar Therapeutics Inc Stock (LRMR) Company Profile

Name

Larimar Therapeutics Inc

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

844-511-9056

Address

THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

LRMR's Discussions on Twitter

Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-19-22	Initiated	Guggenheim	Buy
Feb-15-22	Downgrade	William Blair	Outperform → Mkt Perform
Feb-10-21	Initiated	JMP Securities	Mkt Outperform
Feb-01-21	Initiated	William Blair	Outperform

Larimar Therapeutics Inc Stock (LRMR) Latest News

Nov 04, 2024

What is HC Wainwright's Estimate for LRMR FY2024 Earnings? - MarketBeat

Nov 04, 2024

Nov 02, 2024

HC Wainwright Reiterates “Buy” Rating for Larimar Therapeutics (NASDAQ:LRMR) - Defense World

Nov 02, 2024

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Holdings Cut by Assenagon Asset Management S.A. - MarketBeat

Nov 02, 2024

Nov 01, 2024

Larimar Therapeutics Inc Reports Q3 2024 Net Loss of $15.5 Milli - GuruFocus.com

Nov 01, 2024

Oct 31, 2024

Larimar Therapeutics (NASDAQ:LRMR) Announces Quarterly Earnings Results, Beats Expectations By $0.13 EPS - MarketBeat

Oct 31, 2024

Larimar Therapeutics (NASDAQ:LRMR) Receives "Buy" Rating from HC Wainwright - MarketBeat

Oct 31, 2024

Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MSN

Oct 31, 2024

Larimar Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Oct 30, 2024

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results - GlobeNewswire

Oct 30, 2024

Oct 26, 2024

(LRMR) Investment Analysis and Advice - Stock Traders Daily

Oct 26, 2024

Oct 24, 2024

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Oct 24, 2024

Larimar Therapeutics (NASDAQ:LRMR) Trading Up 6.8%Here's Why - MarketBeat

Oct 24, 2024

Oct 20, 2024

Larimar Therapeutics (NASDAQ:LRMR) Now Covered by Analysts at Oppenheimer - Defense World

Oct 20, 2024

Oct 17, 2024

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth - Yahoo Finance

Oct 17, 2024

Oct 16, 2024

Larimar initiated with bullish view at Oppenheimer on lead drug - MSN

Oct 16, 2024

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock - Benzinga

Oct 16, 2024

Larimar stock gets bullish view at Oppenheimer (LRMR:NASDAQ) - Seeking Alpha

Oct 16, 2024

Oppenheimer Begins Coverage on Larimar Therapeutics (NASDAQ:LRMR) - MarketBeat

Oct 16, 2024

Oct 15, 2024

(LRMR) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Oct 15, 2024

Oct 10, 2024

Millennium Management LLC Boosts Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat

Oct 10, 2024

Oct 09, 2024